ENGN Insider Philip Astley-Sparke Buys 31,000 Shares

Insider Buying and Selling at enGene Therapeutics Inc.

Philip Astley-Sparke acquired 31,000 shares of enGene Therapeutics Inc. (NASDAQ:ENGN) on June 16, 2026. This transaction expands the insider's stake in the company during a period when several other key figures also made purchases. Form 4 filings with securities regulators detail the transaction date and share volume, forming part of a broader group of insider trades recorded on that same day.

A Group of Insiders Add Shares on June 16

Several other insiders joined Philip Astley-Sparke in acquiring stock on June 16, 2026. Michael Heffernan bought 31,000 shares on that date. Paul Hastings picked up 31,000 shares, and Lota Zoth also acquired 31,000 shares. Wouter Joustra and Richard Glickman each purchased 31,000 shares as well. Meanwhile, Interim Chief Medical Officer William Grossman added a larger block of 231,000 shares on the exact same day, expanding the total volume bought across the leadership team.

Stock Valuation and Trading Levels

enGene Therapeutics shares recently traded around $1.74. The equity has moved within a wide 52-week range, reaching a low of $1.40 and a high of $12.25. The current price sits below both its 50-day moving average of $1.83 and its 200-day moving average of $5.36. The firm holds a market capitalization of approximately $131.4 million.

Analysts Set New Price Targets

Wall Street firms continue to track the biotechnology company. On September 8, 2026, HC Wainwright & Co. reiterated a buy rating and maintained a $4.00 price target. Shortly after, on September 9, 2026, Citizens reiterated a market perform rating on the stock without providing a new price target. Across the broader analyst community, the company carries a consensus hold recommendation alongside a mean price target of $3.29 based on seven analyst opinions.

About enGene Therapeutics Inc.

enGene Therapeutics Inc. operates as a clinical-stage biotechnology company based in Montreal, Canada. The firm focuses on developing genetic medicines designed to help patients suffering from bladder cancer. Its lead product candidate, detalimogene voraplasmid, functions as a monotherapy for non-muscle invasive bladder cancer. The pipeline also includes the LEGEND trial, which is currently in Phase 2 clinical testing.

What to Watch Next for ENGN

Investors will keep an eye on upcoming clinical trial updates and regulatory news regarding the company's bladder cancer pipeline. The next financial reporting date is scheduled for January 4, 2027. Market participants should review subsequent Form 4 filings to track any further insider transactions or changes in institutional ownership.